Vivek Agnihotri begins shooting for his new venture, ‘The Vaccine War’

Public TV English
2 Min Read

NEW DELHI: Bollywood director Vivek Agnihotri on Wednesday began the shooting of his next directorial film ‘The Vaccine War’.

Taking to Instagram, Vivek shared a post which he captioned, “GM. We live for new things. New happiness. New laughters. New challenges. Yet, we feel comfortable in the old & established and stick to it. This contradiction gives suffering. Fastest and surest way to find happiness: Jump into uncertainty. The unknown. #CreativeConsciousness.”

In the post, Vivek shared a picture of the screenplay of the film and the clapboard. Helmed by Vivek, the film is slated to hit the theatres on the occasion of Independence Day 2023 in 11 languages. The official announcement of the star cast of the film is still awaited.

Soon after the makers announced the news, fans swamped the comment section and shared their excitement for the upcoming project. “Another masterpiece loading”, a fan commented. Another fan wrote, “He always comes up with most important topics hidden from people and presents them with percent honesty”.

Speaking about the film, Vivek Ranjan Agnihotri had earlier said, “When ‘The Kashmir Files’ was postponed during the Covid lockdown, I started researching on it. Then, we started researching with the scientists of ICMR and NIV who made our own vaccines possible. Their story of struggle and sacrifice was overwhelming and, while researching, we understood how these scientists fought a war waged against India, not just by foreign agencies, but even our own people. Yet, we won against superpowers by making the fastest, cheapest and safest vaccine. I thought this story must be told so that every Indian can feel proud of their country”.

Moreover, he further added, “This will be India’s first pure science film about a bio-war we had no idea about.” ‘The Vaccine War’ will be facing a big Bollywood clash with John Abraham’s upcoming film ‘Tariq’ which is also based on a true story. (ANI)

Share This Article
Exit mobile version